SEC Form 4 · accession 0001144204-15-027951
Cytosorbents Corp · CTSO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Vincent Capponi
Officer — Chief Operating Officer
Period of report
Apr 24, 2015
Accepted (ET)
May 6, 2015 · 4:12 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001175151
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Apr 24, 2015 | M | 4,000 | $0.875 | A | 20,724 | D | |
| Common Stock | Apr 24, 2015 | S | 4,000 | $7.50 | D | 16,724 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF2,F4 | $0.875 | Apr 24, 2015 | M | 4,000 | D | — | Jun 25, 2018 | Common Stock | 4,000 | 80,000 | D |
Explanation of responses
- F1Stock option exercise and open market sale conducted pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
- F2This option has been adjusted to reflect the twenty-five-for-one (25:1) reverse split of the common stock of CytoSorbents Corporation that occurred on December 3, 2014.
- F3The number of shares of common stock held by the reporting person has been reduced to reflect the twenty-five-for-one (25:1) reverse split described above.
- F4This option vested and became exercisable as to 25% of the shares on each of June 25, 2008, June 25, 2009, June 25, 2010 and June 25, 2011.